Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160289 · ClinicalTrials.gov registry record · Phase 2
A Study of LY900010 in Erectile Dysfunction
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 410
- Enrollment target
NCT01160289: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT01160289 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 410 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (208% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01160289, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 410 participants
- Enrollment target
Study Summary
The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.
Primary Outcome
The IIEF EF domain score was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF self-reported questionnaire. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.
Interventions
- DRUG tadalafil
- DRUG LY2452473
- DRUG placebo (tadalafil)
- DRUG placebo (LY2452473)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT01160289 record still lists
NCT01160289 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (208% higher).
The record links to 0 conditions, and to 4 interventions - of which tadalafil is the first listed.
NCT01160289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01160289 about?
NCT01160289 is a clinical study titled "A Study of LY900010 in Erectile Dysfunction". The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.
What is the current status of trial NCT01160289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 410 participants. The study started on 2010-10. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01160289?
The interventions under investigation include: tadalafil (DRUG), LY2452473 (DRUG), placebo (tadalafil) (DRUG), placebo (LY2452473) (DRUG).
Who is sponsoring clinical trial NCT01160289?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01160289's enrollment target sits among peer trials
410 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05751473 · 410 participants · NA
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia